LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
Lenvatinib plus pembrolizumab did not improve efficacy versus docetaxel in participants with stage IV NSCLC that progressed on anti‒programmed cell death protein 1 or anti-programmed cell death ligand 1 therapy and platinum-containing chemotherapy. There were no unexpected safety signals. More effective therapies are needed for this patient population.
Authors
- Helena Linardou (ORCID: https://orcid.org/0000-0002-2906-6607)
- Alexey Smolin (ORCID: https://orcid.org/0000-0002-3023-0515)
- Rina Hui (ORCID: https://orcid.org/0000-0003-0696-7442)
- Adam J. Schoenfeld (ORCID: https://orcid.org/0000-0002-2644-1416)
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Chinyere E. Okpara (ORCID: https://orcid.org/0000-0002-5621-9138)
- Sofia Baka
- Debra Kush
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- Vincenzo Di Noia (ORCID: https://orcid.org/0000-0003-2009-5791)
- Luis Paz‐Ares (ORCID: https://orcid.org/0000-0002-1947-3364)
- Diego Cortinovis (ORCID: https://orcid.org/0000-0001-7611-7369)
- Delvys Rodríguez‐Abreu (ORCID: https://orcid.org/0000-0003-0506-1366)
- Corina E. Dutcus (ORCID: https://orcid.org/0000-0003-3483-716X)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Frédéric Bigot (ORCID: https://orcid.org/0000-0001-5890-107X)
- Justin F. Gainor (ORCID: https://orcid.org/0000-0001-8697-4081)
- Xuan Deng (ORCID: https://orcid.org/0000-0002-4382-5665)
- Andrew Song (ORCID: https://orcid.org/0000-0001-8386-4397)
- Samreen Ahmed
- Makoto Nishio
- Sameh Daher
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yonsei University (KR)
- Hospital Universitario Insular de Gran Canaria (ES)
- Interbalkan Medical Center (GR)
- Massachusetts General Hospital (US)
- Hospital Universitario 12 De Octubre (ES)
- Institut de Cancérologie de l'Ouest (FR)
- Burdenko Neurosurgery Institute (RU)
- Eisai (United Kingdom) (GB)
- Metropolitan Hospital (GR)
- Eisai (United States) (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1016/j.jtho.2025.05.020
- Citations
- 15
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 15.68
Funders
- Eisai